IntriCon (NASDAQ:IIN) had its price target boosted by stock analysts at Stifel Nicolaus from $65.00 to $70.00 in a research note issued to investors on Friday, September 21st, Marketbeat Ratings reports. The firm currently has a “buy” rating on the technology company’s stock. Stifel Nicolaus’ price target indicates a potential upside of 49.00% from the stock’s current price.
IIN has been the topic of a number of other research reports. Dougherty & Co lowered IntriCon from a “buy” rating to a “neutral” rating and set a $12.00 target price on the stock. in a report on Tuesday, September 11th. TheStreet raised IntriCon from a “c+” rating to a “b” rating in a report on Friday, August 31st. B. Riley boosted their target price on IntriCon from $62.00 to $73.00 and gave the company a “buy” rating in a report on Wednesday, August 22nd. Finally, Zacks Investment Research raised IntriCon from a “hold” rating to a “buy” rating and set a $50.00 target price on the stock in a report on Wednesday, July 11th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $51.25.
Shares of IIN traded down $2.08 during midday trading on Friday, hitting $46.98. The company had a trading volume of 408,800 shares, compared to its average volume of 174,372. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.85 and a current ratio of 1.56. The stock has a market capitalization of $501.00 million, a PE ratio of 162.00, a PEG ratio of 6.66 and a beta of 0.58. IntriCon has a 1 year low of $10.40 and a 1 year high of $76.80.
IntriCon (NASDAQ:IIN) last posted its earnings results on Wednesday, July 25th. The technology company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.15. The firm had revenue of $30.16 million during the quarter, compared to analysts’ expectations of $26.10 million. IntriCon had a return on equity of 19.76% and a net margin of 4.32%. Analysts predict that IntriCon will post 0.7 EPS for the current year.
In related news, Director Philip Irving Smith sold 10,000 shares of the company’s stock in a transaction on Friday, August 31st. The stock was sold at an average price of $74.18, for a total transaction of $741,800.00. Following the transaction, the director now owns 6,667 shares of the company’s stock, valued at $494,558.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 21.20% of the company’s stock.
A number of hedge funds have recently made changes to their positions in IIN. BlackRock Inc. grew its holdings in IntriCon by 1,236.5% during the second quarter. BlackRock Inc. now owns 419,019 shares of the technology company’s stock worth $16,886,000 after acquiring an additional 387,668 shares during the period. Integrated Investment Consultants LLC acquired a new position in IntriCon during the second quarter worth $308,000. Northern Trust Corp grew its holdings in IntriCon by 257.6% during the second quarter. Northern Trust Corp now owns 90,616 shares of the technology company’s stock worth $3,651,000 after acquiring an additional 65,276 shares during the period. Allianz Asset Management GmbH purchased a new stake in IntriCon during the first quarter worth $1,050,000. Finally, Mackay Shields LLC purchased a new stake in IntriCon during the second quarter worth $963,000. 42.18% of the stock is currently owned by hedge funds and other institutional investors.
IntriCon Company Profile
IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. The company operates in two segments, Body Worn Devices and Hearing Health Direct-To-Consumer. It offers micro-miniature products, microelectronics; micro-mechanical assemblies; high-precision injection-molded plastic components; and assemblies and software solutions for medical bio-telemetry devices, hearing healthcare, and professional audio communication devices markets.
See Also: Day Trading
Receive News & Ratings for IntriCon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntriCon and related companies with MarketBeat.com's FREE daily email newsletter.